We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verseon (DI) | LSE:VSN | London | Ordinary Share | COM USD0.001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 74.00 | 70.00 | 78.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMVSN
RNS Number : 6801G
Verseon Corporation
09 August 2016
For immediate release 9 August 2016
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Verseon (AIM:VSN), a technology-based pharmaceutical company, announces that application has been made for 1,875 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM (the "Issuance"). The Issuance is in connection with the Verseon Corporation 2015 Equity Incentive Plan and pursuant to the regularly scheduled vesting of previously granted restricted stock units.
The new Common Shares will rank pari passu with the Company's existing Common Shares. Admission to trading on AIM is expected to take place on 10 August 2016 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 151,388,766 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,388,766. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
- Ends -
For further information:
Hot Features
Premium
Verseon Corporation Tel: +1 (510) 225 9000
Arthur Shmurun / Amy www.verseon.com
Thai
Cenkos (Nomad & Broker) Tel: +44 (0) 20 7397
8900
Mark Connelly / Harry
Pardoe
Financial and business media enquiries:
Buchanan Tel: +44 (0) 20 7466
5000
Henry Harrison-Topham www.buchanan.uk.com
/ Steph Watson
Verseon@buchanan.uk.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSEAEPNEDSKEFF
(END) Dow Jones Newswires
August 09, 2016 06:40 ET (10:40 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
